NS-229, a novel Janus kinase 1 inhibitor, ameliorates eosinophilic vasculitis in an ovalbumin-induced mouse model by modulating multiple cytokine signaling pathways.
Saved in:
| Title: | NS-229, a novel Janus kinase 1 inhibitor, ameliorates eosinophilic vasculitis in an ovalbumin-induced mouse model by modulating multiple cytokine signaling pathways. |
|---|---|
| Authors: | Kageyama K; Discovery Research Laboratories, Nippon Shinyaku Co, Ltd, Kyoto, Japan. Electronic address: ki.kageyama@po.nippon-shinyaku.co.jp., Kikuchi E; Discovery Research Laboratories, Nippon Shinyaku Co, Ltd, Kyoto, Japan., Hoshino N; Discovery Research Laboratories, Nippon Shinyaku Co, Ltd, Kyoto, Japan., Ito M; Discovery Research Laboratories, Nippon Shinyaku Co, Ltd, Kyoto, Japan., Akiyama S; Discovery Research Laboratories, Nippon Shinyaku Co, Ltd, Kyoto, Japan., Shiba Y; Discovery Research Laboratories, Nippon Shinyaku Co, Ltd, Kyoto, Japan. |
| Source: | The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2026 Feb; Vol. 393 (2), pp. 103806. Date of Electronic Publication: 2026 Jan 07. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Society for Pharmacology and Experimental Therapeutics Country of Publication: Netherlands NLM ID: 0376362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1521-0103 |
|---|---|
| DOI: | 10.1016/j.jpet.2026.103806 |
